Company
Avacta Group PLC
LON:AVCT
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
207 stories · page 1 of 11
Avacta soars on another successful clinical study
Avacta shares jumped as the firm hailed the success of its chemotherapy drug
Avacta Group receives orphan drug designation from US FDA
The US FDA designation qualifies the drug developer to receive certain incentives, including seven years of market exclusivity upon drug approval
Avacta moves onto next phase of cancer study
AVA6000 is a novel form of anti-cancer medication doxorubicin that has been modified by Avacta's delivery platform for improved safety
Avacta JV raises funds for stem cell projects
Proceeds from the fundraise will support Investigational New Drug (IND) enabling studies that will underpin a regulatory filing to bring its lead programme to market
Avacta announces second dose escalation in cancer study after positive safety review
CEO Alastair Smith said the treatments have the "potential to deliver safer and affordable oncology drugs that could significantly improve cancer patients' lives"
Archive
Serinus Energy moves closer to start of drilling in Romania
A look at the major movers on the London market on Wednesday
Avacta JV AffyXell agrees drug development collaboration
The deal should enhance the translation of AffyXell's programmes into human trials and accelerate drug development
Avacta full-year results push shares higher
In London, Avacta shares were up 6.7% trading at 68.3p.
Archive
Caspian Sunrise climbs on positive production and financial update
A look at the major movers on the London market on Wednesday